Title of the cohort

European Health Examination Survey

Acronym for cohort

LUX-EHES

Name of Principal Investigator
Title mme
First name  Marie-Lise
Last name LAIR
Address of institution where award is held
Institution
Street Address 1A-B rue Thomas Edison
City SRASSEN
Postcode L-1445
Country

Luxembourg

Website

www.crp-sante.lu

Contact email

marie-lise.lair@crp-sante.lu

Funding source

Health Ministry
Research Ministry

1. The cohort includes, or expects to include, incidence of the following conditions
  • Neurodegenerative disease in general
When studies on the above condition(s) are expected to become possible

2011 – 2015

2a. Stated aim of the cohort

to study public health determinants

2b. Features distinguishing this cohort from other population cohorts

we ask blood sample for biobanking

3a. i) Number of publications that involve use of cohort to date
0
3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)
3b. Publication list/link to where data or publications are accessible (if available)
3c. Information (i.e. research findings) expected to be gained from the population cohort

epdemiological informations public health informations impact of environmental conditions on health and some diseases

4a. Study criteria: age range of participants at recruitment
Age in years from: more 18 years
To (‘until death’ if applicable): 65 years
4b. Study criteria: inclusion criteria

criteria from european health examination survey will be used. People will be randomly selected from the national register.

4c. Study criteria: exclusion criteria

institutionalised people

5. Size of the cohort (i.e. number of participants enrolled)

5,001 – 10,000 participants

6a. Measures used to characterise participants

age, gender, comorbidities, socio economic conditions, socio educative conditions, environmental conditions, lifestyle (tobacco, nutrition, alcoohol, physical activity), medications, diseases, health status, family diseases, use of healthcare, ethnical informations, work conditions, vaccines, anthropometric measurements, blood pressure, blood analysis, visual capacity, auditiv capacity, cognitiv status

6b. Additional measures for participants with a clinical disorder
6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)

No

7. Study design

Cross sectional survey

8. Cases matched by
  • Age
  • Sex
  • Co-morbidities
  • Cognitive function
  • Physical ability
9a. Does the study include a specialised subset of control participants

No

9b. If yes, description of specialised subset of control participants
10a. i) Data collection start date

01-01-2012

10a. ii) Data collection end date

31-12-2013

10a iii) Data collection for this study is
  • At the planning stage
10b. Plans to continue the cohort study beyond the current projected end date
  • Yes – intend to apply for funding
11. Data collected
  • Only through the study
12. System in place to enable re-contact with patients for future studies

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

13a. Format and availability of data stored in a database
Yes/No % available
Data summarised in database  yes
Database is web-based  yes
Database on spreadsheet
Database is on paper
Other (specify)
Language used:

french, german, english, portuges

13b. Format and availability of data held as individual records
Language used:
14a. Are data available to other groups

Yes

14b. Access policy/mechanisms for access if data are available to other groups
  • Apply to PI or co-ordinator at resource
  • Access through collaboration with PI only
  • Access Committee mechanism
  • Local/ regional access
  • National access
  • International access
  • Access restricted to peer-reviewed work
  • Applicant needs to provide separate external ethics approval
15. Data sharing policy specified as a condition of use

Data made publicly available after a specified time point

16a. Are tissues/samples/DNA available to other groups

Yes

16b. i) Description of available tissues/samples/DNA
  • Living donors:blood
  • Living donors: blood derivatives
  • Living donors: DNA
16b. ii) Form available tissues/samples/DNA are supplied in
16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data

Yes

17. Is information on biological characteristics available to other groups

No

Types: Population Cohorts
Member States: Luxembourg
Diseases: Neurodegenerative disease in general
Years: N/A
Database Categories: N/A
Database Tags: N/A

Export as PDF